Compare Adaptive Biotechnologies Corp (ADPT) vs TORM plc (TRMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs TORM plc — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while TORM plc trades at $28.93 (market cap $2.87B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and TORM plc pays a 9.87% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TRMD | |
|---|---|---|
Market Cap | $3.33B | $2.87B |
Sector | Health | Technology |
52-Week High | $22.37 | $34.87 |
52-Week Low | $10.24 | $17.33 |
Enterprise Value | $3.19B | $3.76B |
Dividend Yield | — | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
TRMD trades at $27.99, up 1.05% today, with neutral technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.21 and P/B of 1.26, supported by robust profitability including 24.41% net margin and 15.62% ROE. Recent earnings showed mixed results with Q4 2025 beat but Q1 2026 miss, while Q2 2026 expectations are set at $3.3 EPS. The company maintains strong cash generation with $498.9M operating cash flow in 2025 and recently declared a $0.70 dividend.
Outlook remains positive with 100% analyst buy ratings and improving 2026 revenue guidance to $1.4B. Key opportunities include undervaluation relative to peers and strong dividend yield near 9%. Risks include earnings volatility from tanker market fluctuations and negative net cash flow trends. The stock presents value for income-focused investors despite cyclical industry exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
